Tirzepatide
Research OnlyDual Agonist (GLP-1/GIP)
Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist. It works synergistically to improve glycemic control and support weight loss by enhancing insulin secretion, delaying gastric emptying, and reducing appetite.
Dosing Schedule
| Week | Dose | Units (U-100) |
|---|---|---|
| 1-4 | 2.5 mg | 50 units |
| 5-8 | 5.0 mg | 100 units |
| 9-12 | 7.5 mg | 150 units |
| 13-16 | 10.0 mg | 200 units |
| 17-20 | 12.5 mg | 250 units |
| 21+ | 15.0 mg | 300 units |
Frequency: Inject once weekly subcutaneously.
When you BUY Tirzepatide, you want to know that it's pure. We recommend using trusted suppliers for your research needs.
Visual representation of the dosage ramp-up over the cycle duration.
Reconstitution
2ml
5 mg/mL
10 mg
Add 2.0 mL bacteriostatic water to a 10mg vial for a concentration of 5 mg/mL.
Administration
Timing Strategy
Administer once weekly on the same day each week, with or without meals.
Cycle Length
Titrate dose every 4 weeks. Maximum maintenance dose is 15mg weekly.
Research Benefits
Dual activation of GIP and GLP-1 receptors enhances insulin sensitivity, reduces glucagon secretion, and slows gastric emptying.
Storage Guidelines
Lyophilized: Store at -20°C (-4°F).
Reconstituted: Refrigerate at 2-8°C (36-46°F). Do not freeze.
Research Purposes Only
This information is for educational and research purposes only. These compounds are not approved for human consumption. Always consult with a qualified professional and adhere to local regulations regarding research chemicals.
Concentration
5.00 mg/mL
(5000 mcg/mL)
Injection Volume
0.05 mL
Draw to this mark on U-100 Syringe
Visual representation on a standard U-100 Insulin Syringe